Speaker: Prof. Mukund Chorghade
President, CSO and CTO, THINQ Pharma, 14 Carlson
Circle, Natick, Massachusetts 01760-4205
Title: "Fascinating Personal Adventures in Progression of a
New Chemical Entity from Conception to
Commercialization."
Day and Date: Tuesday, February 03, 2026
Time: 16.00 Hrs.
Venue: Room no. 350, Chemistry Department
Second floor, Annex
------------------------------------------------------------------------
Hosted by Prof. Krishna P. Kaliappan
Abstract We will discuss and exemplify some interesting contributions made by our group to
discovering new chemical entities. Process Chemistry / Route Selection are important
activities in the path of a drug from mind to market. The medicinal chemistry routes for
synthesis although amenable to analogue design are usually low yielding and are fraught
with a plethora of intractable problems such as such as commercially unavailable
reagents and intermediates, capricious and cryogenic reactions that preclude efficient
scale up, tedious chromatography unfavorable atom economy and problems in waste
disposal and management. Considerable research efforts have to be expended in
developing novel, cost efficacious and scalable processes and seamlessly transferring
these technologies to manufacturing operations.
These principles will be demonstrated by our process development efforts on an antiepileptic and an anti-asthma drug that have resulted in amelioration of many of these
problems and removal of significant bottlenecks in the progress of a drug from
conception to commercialization.
Several problems are currently associated with the use of biological systems in studying
drug metabolism.
• In vitro studies produce very small quantities of the product. Primary metabolites are
often hydrophilic and difficult to isolate.
• Animals studies necessitate the sacrifice of animals and are extremely expensive to
conduct. Liver slice preparations are of variable potency; it is difficult to quantitate
the precise stoichiometry of the oxidant.
• Many of the metabolites are not amenable to organic synthesis by conventional
routes.
We present rare examples of porphyrin-mediated oxidations of sophisticated
pharmaceutical entities. The reactions (mimics of cytochrome P-450) are generally
applicable and have been used in our laboratories to achieve hydroxylation and Ndemethylation on numerous other substrates. This approach affords and efficient method
for the systematic preparation and identification of the entire spectrum of metabolites
from a chosen drug.